PUBLISHER: TechNavio | PRODUCT CODE: 1432248
PUBLISHER: TechNavio | PRODUCT CODE: 1432248
The premenstrual syndrome market is forecasted to grow by USD 276.72 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the premenstrual syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness and reporting about PMS, collaboration and partnerships among vendors, and growing preference for herbal and dietary supplements.
Technavio's premenstrual syndrome market is segmented as below:
Market Scope | |
---|---|
Base Year | 2024 |
End Year | 2028 |
Series Year | 2024-2028 |
Growth Momentum | Accelerate |
YOY 2024 | 3.22% |
CAGR | 3.69% |
Incremental Value | $276.72mn |
By Drug Class
By Distribution Channel
By Geographical Landscape
This study identifies the robust adoption of telemedicine as one of the prime reasons driving the premenstrual syndrome market growth during the next few years. Also, high investment on r and d on PMS drugs and menstrual health initiatives by regional governments will lead to sizable demand in the market.
The report on the premenstrual syndrome market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premenstrual syndrome market vendors that include AbbVie Inc., Aspen Pharmacare Holdings Ltd, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Herbalife International of America Inc., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Octavius Pharma Pvt. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Recordati S.p.A, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the premenstrual syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Exhibits: